Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABAA inverse agonist.
Fiche publication
Date publication
octobre 2019
Journal
British journal of pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HERAULT Yann
Tous les auteurs :
Duchon A, Gruart A, Albac C, Delatour B, Zorrilla de San Martin J, Delgado-García JM, Hérault Y, Potier MC
Lien Pubmed
Résumé
Excessive GABAergic inhibition contributes to cognitive dysfunctions in Down syndrome (DS). Selective negative allosteric modulators (NAMs) of α5-containing GABA receptors such as α5IA restore learning and memory deficits in Ts65Dn mice modelling DS. This study aimed at testing long-lasting effects of α5IA on in vivo long-term potentiation (LTP) and behavior in Ts65Dn mice.
Référence
Br. J. Pharmacol.. 2019 Oct 25;: